Resources from the same session
1766MO - Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (nmHSPC) patients (pts) with high-risk biochemical recurrence (BCR) from the EMBARK study
Presenter: Stephen Freedland
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
1767MO - External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived model in high-risk localized (M0)/metastatic (M1) prostate cancer (PCa) starting androgen deprivation therapy (ADT) in the docetaxel (Doc) or abiraterone (AAP) phase III STAMPEDE trials
Presenter: Charles Parker
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
1768MO - Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: Analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisons
Presenter: Craig Jones
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1766MO, 1767MO and 1768MO
Presenter: Boris Hadaschik
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
1771MO - Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study
Presenter: Julie Graff
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
1772MO - Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study
Presenter: Christian Gratzke
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA85 - Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
Presenter: Kim Nguyen Chi
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA86 - Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial
Presenter: Henrik Grönberg
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast